{"id":"https://openalex.org/W2590585599","doi":"https://doi.org/10.1182/blood.v116.21.1323.1323","title":"Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome","display_name":"Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome","publication_year":2010,"publication_date":"2010-11-19","ids":{"openalex":"https://openalex.org/W2590585599","doi":"https://doi.org/10.1182/blood.v116.21.1323.1323","mag":"2590585599"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v116.21.1323.1323","doi":"https://doi.org/10.1182/blood.v116.21.1323.1323","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.1323.1323","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029390145","display_name":"John Koreth","orcid":"https://orcid.org/0000-0002-7428-1330","observed_orcids":["https://orcid.org/0000-0002-7428-1330"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Koreth","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041324758","display_name":"Melinda Ann Biernacki","orcid":"https://orcid.org/0000-0002-9527-0905","observed_orcids":["https://orcid.org/0000-0002-9527-0905"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Melinda Biernacki","raw_affiliation_strings":["Department of Medicine, Brown University, Providence, RI, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Brown University, Providence, RI, USA,","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029218146","display_name":"Julie Aldridge","orcid":"https://orcid.org/0000-0001-6724-7591","observed_orcids":["https://orcid.org/0000-0001-6724-7591"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Julie Aldridge","raw_affiliation_strings":["Division of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045479163","display_name":"Haesook T. Kim","orcid":"https://orcid.org/0000-0003-4889-6849","observed_orcids":["https://orcid.org/0000-0003-4889-6849"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haesook T Kim","raw_affiliation_strings":["Division of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074589634","display_name":"Edwin Pascal Alyea","orcid":"https://orcid.org/0000-0002-1885-8430","observed_orcids":["https://orcid.org/0000-0002-1885-8430"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin P Alyea","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029278364","display_name":"Corey S. Cutler","orcid":"https://orcid.org/0000-0001-8728-4314","observed_orcids":["https://orcid.org/0000-0001-8728-4314"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey Cutler","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031812464","display_name":"Vincent T. Ho","orcid":"https://orcid.org/0000-0001-6839-3996","observed_orcids":["https://orcid.org/0000-0001-6839-3996"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vincent T. Ho","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047701430","display_name":"Catherine J. Wu","orcid":"https://orcid.org/0000-0002-3348-5054","observed_orcids":["https://orcid.org/0000-0002-3348-5054"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine J Wu","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054037976","display_name":"Joseph H. Antin","orcid":"https://orcid.org/0000-0003-4627-1714","observed_orcids":["https://orcid.org/0000-0003-4627-1714"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph H. Antin","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068050082","display_name":"Robert J. Soiffer","orcid":"https://orcid.org/0000-0002-5810-1192","observed_orcids":["https://orcid.org/0000-0002-5810-1192"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert J Soiffer","raw_affiliation_strings":["Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5029218146","https://openalex.org/A5041324758","https://openalex.org/A5068050082"],"corresponding_institution_ids":["https://openalex.org/I27804330","https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.40050892,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"116","issue":"21","first_page":"1323","last_page":"1323"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11189","display_name":"Transplantation: Methods and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/engraftment-syndrome","display_name":"engraftment syndrome","score":0.953000009059906},{"id":"https://openalex.org/keywords/hla-typing","display_name":"HLA typing","score":0.5879999995231628},{"id":"https://openalex.org/keywords/risk-factors","display_name":"risk factors","score":0.7020000219345093},{"id":"https://openalex.org/keywords/age-as-risk-factor","display_name":"age as risk factor","score":0.6499999761581421},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.6119999885559082},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6800000071525574},{"id":"https://openalex.org/keywords/corticosteroid-therapy","display_name":"corticosteroid therapy","score":0.35499998927116394},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.7609999775886536},{"id":"https://openalex.org/keywords/myeloid-neoplasms","display_name":"myeloid neoplasms","score":0.5889999866485596},{"id":"https://openalex.org/keywords/lymphoid-malignancies","display_name":"lymphoid malignancies","score":0.9520000219345093},{"id":"https://openalex.org/keywords/plasma-cell-malignancy","display_name":"plasma cell malignancy","score":0.6919999718666077},{"id":"https://openalex.org/keywords/conditioning-regimen","display_name":"conditioning regimen","score":0.39500001072883606},{"id":"https://openalex.org/keywords/hct-comorbidity-index","display_name":"HCT-comorbidity index","score":0.7289999723434448},{"id":"https://openalex.org/keywords/non-cardiogenic-pulmonary-edema","display_name":"non-cardiogenic pulmonary edema","score":0.7279999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7455997467041016},{"id":"https://openalex.org/C88879693","wikidata":"https://www.wikidata.org/wiki/Q217690","display_name":"Cumulative incidence","level":3,"score":0.6489403247833252},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.6333555579185486},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.5914736986160278},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5829156637191772},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4744183421134949},{"id":"https://openalex.org/C2778880498","wikidata":"https://www.wikidata.org/wiki/Q1986672","display_name":"Total body irradiation","level":4,"score":0.44385066628456116},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3727767765522003},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33420759439468384},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.12493300437927246},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.09098008275032043}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v116.21.1323.1323","doi":"https://doi.org/10.1182/blood.v116.21.1323.1323","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.1323.1323","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2009568945","https://openalex.org/W4245103048","https://openalex.org/W2075388288","https://openalex.org/W2981081582","https://openalex.org/W2947288948","https://openalex.org/W1502793109","https://openalex.org/W4307199223","https://openalex.org/W4311189979","https://openalex.org/W2025908314","https://openalex.org/W2604839852"],"abstract_inverted_index":{"Abstract":[0,1],"1323":[2],"Engraftment":[3],"syndrome":[4],"(ES),":[5],"typically":[6],"characterized":[7],"by":[8],"non-infectious":[9],"fever,":[10],"rash":[11],"and/or":[12],"non-cardiogenic":[13],"pulmonary":[14],"edema,":[15],"is":[16,29,400],"a":[17,56,150,247,272,376,406],"complication":[18],"of":[19,59,94,152,198,223,244,250,264,324,337,379,395,410,421,434],"autologous":[20],"and":[21,43,49,97,103,115,121,164,169,175,209,216,225,231,330,357,402,412,423],"allogeneic":[22],"hematopoietic":[23],"stem":[24,161],"cell":[25,162],"transplantation":[26],"(HSCT).":[27],"There":[28],"no":[30],"data":[31],"on":[32],"ES":[33,45,277,289,304,316,329,342,380,386,399,417,428],"after":[34,381],"syngeneic":[35,40,65,382,385],"HSCT.":[36,383],"We":[37],"retrospectively":[38],"analyzed":[39],"HSCT":[41,66,390],"outcomes":[42],"determined":[44],"incidence,":[46],"risk":[47,273],"factors,":[48],"prognostic":[50],"impact.":[51],"32":[52],"adult":[53],"patients":[54,235,287,302],"with":[55,253,288,303,315,328,341,398],"median":[57,196],"age":[58,268],"46":[60],"years":[61,202,270],"(range,":[62,203],"22\u201360)":[63],"underwent":[64],"at":[67],"our":[68],"institution":[69],"between":[70],"July":[71],"1986-April":[72],"2009,":[73],"primarily":[74],"for":[75,240,275],"hematologic":[76],"malignancies":[77],"(31%":[78],"myeloid,":[79],"66":[80],"%":[81],"lymphoid-including":[82],"16%":[83],"plasma":[84],"cell).":[85],"Syngeneic":[86],"donor":[87,158,190],"typing":[88],"methods":[89],"varied":[90],"over":[91],"the":[92,393],"time-period":[93],"this":[95],"report":[96],"included:":[98],"serologic":[99],"HLA":[100,109,117],"Class":[101,110,118],"I":[102,111],"II":[104,119],"typing;":[105,112,120],"confirmatory":[106],"SSP":[107,116],"molecular":[108,113],"PCR-RFLP":[114],"STR":[122],"genotyping":[123],"using":[124],"ABI":[125],"Profile":[126],"Plus":[127],"Kit":[128],"Human":[129],"Identity":[130],"markers.":[131],"Patient":[132,267],"characteristics:":[133],"15":[134,234],"(47%)":[135,236],"were":[136],"male;":[137],"28":[138],"(88%)":[139],"had":[140,172],"high-risk":[141,176],"disease;":[142],"18":[143],"(56%)":[144],"received":[145,157,246],"total-body":[146],"irradiation":[147],"(TBI)":[148],"as":[149,414,425],"component":[151],"myeloablative":[153],"conditioning;":[154],"16":[155],"(50%)":[156],"peripheral":[159],"blood":[160],"infusion;":[163],"14":[165],"(41%),":[166],"10":[167,242],"(31%)":[168],"9":[170],"(28%)":[171],"low-,":[173],"intermediate-":[174],"HCT-comorbidity":[177],"index":[178],"score":[179],"respectively.":[180,218,233],"No":[181,431],"graft-versus-host-disease":[182],"prophylaxis,":[183],"T-cell":[184],"depletion,":[185],"or":[186,188],"pre-emptive":[187],"prophylactic":[189],"lymphocyte":[191],"infusion":[192],"was":[193,200,214,229,271,283,299,313,326,339],"utilized.":[194],"The":[195],"duration":[197],"follow-up":[199],"6.1":[201],"3.7":[204],"months-18.1":[205],"years).":[206],"5-year":[207,219,297,311,321,334],"progression-free":[208],"overall":[210,220],"survival":[211,391],"(PFS,":[212],"OS)":[213],"52%":[215],"67%":[217],"cumulative":[221,322,335],"incidence":[222,323,336,378],"relapse":[224,325],"non-relapse":[226],"mortality":[227],"(NRM)":[228],"37.6%":[230],"10.2%":[232],"met":[237],"diagnostic":[238],"criteria":[239],"ES,":[241],"(67%)":[243],"whom":[245],"brief":[248],"course":[249],"systemic":[251],"steroids":[252],"prompt":[254],"clinical":[255],"response":[256],"in":[257,286,293,301,307,405],"all":[258],"except":[259],"one":[260],"patient":[261],"(who":[262],"died":[263],"respiratory":[265],"failure).":[266],"\u226550":[269],"factor":[274],"developing":[276],"(p=0.05).":[278],"Median":[279],"time":[280],"to":[281,436],"engraftment":[282],"12":[284],"days":[285,292],"vs.":[290,305,317,343],"11.5":[291],"those":[294,308],"without":[295,309,319,332,345],"ES.":[296],"PFS":[298,356],"47%":[300],"56%":[306],"(p=0.37).":[310],"OS":[312,358],"63%":[314],"71%":[318],"(p=0.8).":[320],"32%":[327],"44%":[331],"(p=0.68).":[333],"NRM":[338,397,413,424],"21%":[340],"0%":[344],"(p=0.06).":[346],"In":[347,372],"multivariable":[348],"Cox-models":[349],"only":[350],"myeloid":[351],"diagnosis":[352],"(vs.":[353],"lymphoid)":[354],"impaired":[355],"(HR":[359],"4.83,":[360],"95%":[361,367],"CI":[362,368],"1.33\u201317.53,":[363],"p=0.02;":[364],"HR":[365],"8.47,":[366],"1.73\u201341.58,":[369],"p<0.01":[370],"respectively).":[371],"summary,":[373],"we":[374],"document":[375],"high":[377],"While":[384],"did":[387],"not":[388],"impact":[389],"outcomes,":[392],"trend":[394],"increased":[396],"concerning":[401],"needs":[403],"re-evaluation":[404],"larger":[407],"cohort.Figure:Cumulative":[408],"Incidence":[409,420],"Relapse":[411,422],"Competing":[415,426],"Risks-by":[416,427],"cohortFigure:.":[418],"Cumulative":[419],"cohort":[429],"Disclosures:":[430],"relevant":[432],"conflicts":[433],"interest":[435],"declare.":[437]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2017-03-03T00:00:00"}